Afra TP, et al. - Researchers performed a prospective, observer-blinded, active-controlled, randomized clinical trial to assess the efficacy of topical tazarotene gel, 0.1%, in treating atrophic postacne scarring. They used a split-face study design that included 34 matched treatment areas and identified significant and comparable clinically relevant improvement from baseline in facial atrophic acne scarring at the 6-month follow-up visit for tazarotene and microneedle therapy, the active control. This suggests that both treatments were comparable for the overall improvement of quantitative facial acne scar severity.